Alphabet Inc’s TScan Therapeutics TCRX Stock Holding History

Alphabet Inc’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,077,080	Closed	-$1.96M	–	34
2025 Q3	$1.96M	Hold	1,077,080	–	–	0.08%	26
2025 Q2	$1.56M	Hold	1,077,080	–	–	0.07%	26
2025 Q1	$1.49M	Hold	1,077,080	–	–	0.09%	26
2024 Q4	$3.27M	Hold	1,077,080	–	–	0.19%	20
2024 Q3	$5.36M	Hold	1,077,080	–	–	0.29%	21
2024 Q2	$6.3M	Hold	1,077,080	–	–	0.32%	19
2024 Q1	$8.55M	Hold	1,077,080	–	–	0.34%	20
2023 Q4	$6.28M	Hold	1,077,080	–	–	0.29%	23
2023 Q3	$2.76M	Hold	1,077,080	–	–	0.18%	27
2023 Q2	$2.69M	Hold	1,077,080	–	–	0.14%	29
2023 Q1	$2.26M	Hold	1,077,080	–	–	0.13%	33
2022 Q4	$1.65M	Hold	1,077,080	–	–	0.1%	37
2022 Q3	$3.29M	Hold	1,077,080	–	–	0.17%	34
2022 Q2	$3.39M	Hold	1,077,080	–	–	0.18%	37
2022 Q1	$3.02M	Hold	1,077,080	–	–	0.1%	45
2021 Q4	$4.85M	Hold	1,077,080	–	–	0.12%	43
2021 Q3	$8.98M	Buy	+1,077,080	New	+$9.99M	0.21%	30

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Alphabet Inc's TCRX Position: Q4 2025 in Review

Alphabet Inc sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 1,077,080 shares — an estimated $1.96M sold.

Alphabet Inc first reported a position in TCRX in Q3 2021 and held it in 17 quarters. The position peaked at $8.98M in Q3 2021. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

Alphabet Inc reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
Alphabet Inc sold 1,077,080 TScan Therapeutics shares in Q4 2025, an estimated $1.96M.
Alphabet Inc first reported a position in TScan Therapeutics in Q3 2021 and held it in 17 quarters.
Alphabet Inc's TScan Therapeutics position peaked at $8.98M in Q3 2021.
61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Alphabet Inc's 13F filing for Q4 2025, filed 13 Feb 2026.